Drugs Xagena
The FDA ( U.S. Food and Drug Administration ) has approved Erleada ( Apalutamide ) for the treatment of patients with prostate cancer that has not spread ( non-metastatic ), but that continues to grow ...
The European Commission ( EC ) has granted marketing authorisation for Erleada ( Apalutamide ), a next generation oral androgen receptor inhibitor for the treatment of adult patients with non-metastat ...
The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to include the treatment of adult men with metastatic hormone-sensitive prostate canc ...
